ProMIS Neurosciences, Inc. (PMN)
NASDAQ: PMN · Real-Time Price · USD
10.85
-0.25 (-2.25%)
At close: Apr 28, 2026, 4:00 PM EDT
11.18
+0.33 (3.04%)
After-hours: Apr 28, 2026, 4:17 PM EDT
ProMIS Neurosciences Employees
As of December 31, 2025, ProMIS Neurosciences had 11 total employees, including 10 full-time and 1 part-time employees. The number of employees increased by 3 or 37.50% compared to the previous year.
Employees
11
Change (1Y)
3
Growth (1Y)
37.50%
Revenue / Employee
n/a
Profits / Employee
-$3,610,832
Market Cap
97.30M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Seer, Inc. | 124 |
| Inovio Pharmaceuticals | 112 |
| Fractyl Health | 100 |
| NeurAxis | 24 |
| Edesa Biotech | 17 |
| Coya Therapeutics | 8 |
| Aldeyra Therapeutics | 8 |
| Coeptis Therapeutics Holdings | 6 |
PMN News
- 15 days ago - ProMIS Neurosciences Invited to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference - Newsfile Corp
- 4 weeks ago - ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights - GlobeNewsWire
- 5 weeks ago - ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer's Disease/Parkinson's Disease 2026 International Conference (AD/PD™) - GlobeNewsWire
- 2 months ago - ProMIS Neurosciences Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026 - Transcripts
- 2 months ago - ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 3 months ago - ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing - GlobeNewsWire
- 4 months ago - ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer's Disease - GlobeNewsWire
- 4 months ago - ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk - GlobeNewsWire